ESR1 and breast carcinoma: Prevention of ERα degradation by proteasome inhibitors, such as MG132 and lactacystin, disrupts estradiol-induced ERα transactivation in HeLa cervical cancer cells, MCF7 breast cancer cells, and GH3 pituitary cells [6, 8, 20].